Russell Investments Group Ltd. Buys 508,104 Shares of Genmab A/S (NASDAQ:GMAB)

Russell Investments Group Ltd. increased its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 18,959.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 510,784 shares of the company's stock after purchasing an additional 508,104 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.08% of Genmab A/S worth $10,660,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Brandywine Global Investment Management LLC acquired a new stake in shares of Genmab A/S in the fourth quarter worth $33,804,000. JPMorgan Chase & Co. lifted its position in Genmab A/S by 3,049.3% during the 4th quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock worth $8,507,000 after acquiring an additional 394,670 shares during the last quarter. Trexquant Investment LP lifted its position in Genmab A/S by 495.1% during the 4th quarter. Trexquant Investment LP now owns 379,936 shares of the company's stock worth $7,929,000 after acquiring an additional 316,089 shares during the last quarter. FMR LLC boosted its holdings in Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company's stock valued at $6,782,000 after acquiring an additional 33,076 shares during the period. Finally, LPL Financial LLC grew its position in shares of Genmab A/S by 3.3% in the fourth quarter. LPL Financial LLC now owns 195,436 shares of the company's stock valued at $4,079,000 after purchasing an additional 6,288 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Up 1.0 %

Genmab A/S stock traded up $0.19 on Tuesday, hitting $19.51. The company's stock had a trading volume of 1,826,066 shares, compared to its average volume of 1,025,098. The company has a fifty day moving average price of $20.48 and a 200-day moving average price of $21.25. The firm has a market cap of $12.91 billion, a P/E ratio of 11.21, a price-to-earnings-growth ratio of 2.65 and a beta of 1.07. Genmab A/S has a one year low of $17.24 and a one year high of $30.41.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target for the company in a report on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. Finally, HC Wainwright reissued a "buy" rating and issued a $37.00 price target (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Genmab A/S has a consensus rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.